Quick answer: latest quarter results, by ticker or company name

Home / CYBN.NE / Company Profile

Cybin Inc

CYBN.NE | Healthcare | NEO
🌐 Website 📊 Reports 📈 Financials
$9.04
+0.45 (+5.24%)

Key Metrics

Market Cap
$218.82M
P/E Ratio
-1.75
EPS
$-5.17
Beta
N/A
Dividend Yield
N/A
ROE
-54.55%
Current Ratio
11.93

Company Information

Industry
Biotechnology

About Cybin Inc

Cybin Inc a biopharmaceutical company focuses on developing psychedelicbased therapeutics The companys development pipeline includes CYB003 a deuterated psilocybin analog to treat major depressive and alcohol use disorders CYB004 a deuterated dimethyltryptamine for treating anxiety disorders and CYB005 a phenethylamine derivative to treat neuroinflammation It has also developed EMBARK a psychedelicassisted psychotherapy The company is headquartered in Toronto Canada

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-11-13 $-1.92 $-0.80 141.4%
2025-06-30 $-1.46 $-1.09 33.9%
2025-02-09 $-0.53 $-1.03 +-48.5%
2024-11-13 $-2.86 $-0.96 197.9%

Financial Ratios (TTM)

Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
0.00%
ROA
-44.48%
Price to Book
1.13
Price to Sales
0.00